Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (July 2017)
29 slides from Stablecoin Development's investor presentation, Jul 17, 2017
Slide 1: Harnessing the Anti-Infective Power of White Blood Cell Chemistry
Harnessing the Anti-Infective Power of White Blood Cell Chemistry to Address Ophthalmic Diseases Afflicting 41 Million Americans NYSE MKT: NBY www.novabay.com July 17, 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: Summary Highlights
Summary Highlights • Specialty Pharma – Commercial stage; Sold by Prescription • Company founded to address antibiotic resistance crisis • Turn-around in 2016 • 2016 sales tripled over 2015 • Cash Flow breakeven achieved for month of Dec’16 • Strong experienced management team • High growth in large
Slide 4: Leading the NovaBay Commercial Transition
Leading the NovaBay Commercial Transition Mark Sieczkarek – Chairman, CEO & President • 40 years in the Life Sciences- Large and Small Companies • Pharmaceutical, Consumer; Diagnostics and Medical Devices; Finance, Sales & Marketing; Manufacturing; Mergers and Acquisitions; General Management • Bris
Slide 5: The Foundation of NovaBay Technology: Neutrox
The Foundation of NovaBay Technology Commercializing Products That Mimic the Anti-Microbial Power of Neutrophils Bacteria White Blood Cell Red blood cells Neutrophil NovaBay’s Breakthrough: Neutrox® • Proprietary formulation, pure hypochlorous acid (HOCl) • Identical to molecule produced by neutroph
Slide 6: The Foundation of NovaBay Technology
The Foundation of NovaBay Technology Commercializing Products That Mimic the Anti-Microbial Power of Neutrophils White Blood Cell Video 6
Slide 7: Avenova Package Insert Lists Confirmed Time-Kills and Broad Spectrum Activity
Avenova Package Insert Lists Confirmed Time-Kills and Broad Spectrum Activity Related to Most Common Eye Infections 7
Slide 8: Advantages
Advantages Does not ✓ generate Resistance Bacterial ✓Mechanical ✓ removal debridement Anti-biofilm ✓ activity ✓Anti-toxin 8
Slide 9: What is Blepharitis?
What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease • Caused by constant high bacterial load around eyes • Condition is chronic and incurable • Signs and symptoms • Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation • High incidence • 37% of patients
Slide 10: Successful Clinical Study Presented at 2016 ARVO
Successful Clinical Study Presented at 2016 ARVO Confirmed Avenova’s Rapid Time-Kill and Broad Antimicrobial Effects Journal of Clinical Ophthalmology April, 2017 10
Slide 11: Addressing 41 Million Potential Patients in U.S.
Addressing 41 Million Potential Patients in U.S. Blepharitis 24M Dry eye 6M Contact lens Surgery - intolerance Retinal Surgery - Cataract 4M injections Lasik 3M 3M 1M Dry Eye Is the only market segment addressed by Restasis and Xiidra (Effects of these two drugs may be enhanced when used in combinat
Slide 12: Commercial Targets
Commercial Targets Neutrox Mybochorovs Ac N®vaBay’ PHARMA 12
Slide 13: Market Coverage
Market Coverage Northeast (11): 50 Direct Medical Reps in Key Metro Areas Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago-No, Chicago-So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel
Slide 14: Reimbursement: Insurance Coverage Continues to Grow
Reimbursement: Insurance Coverage Continues to Grow 14 14
Slide 15: Extensive Media Campaigns Targeting Dry Eye Underway
Extensive Media Campaigns Targeting Dry Eye Underway Defensive Ads for Restasis Xiidra Launch Promotions (57,000 Rx/Week) (17,000 Rx/Week) 15
Slide 16: How Products Compare in the Management of MGD Dry Eye
How Products Compare in the Management of MGD Dry Eye U.S. Market of 30 Million Patients Avenova Restasis Xiidra Benefits Launch Date Q4, 2014 2003 Q4, 2016 - Blocks Cytokines - Kills Bacteria - Penetrates Biofilm - Blocks Bacterial Toxins - Blocks Lipase None Burning, redness, discharge, Stinging,
Slide 17: Contains Only 2 Ingredients: Pure Hypochlorous Acid + Saline
contains only 2 Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Hypochlor Acuicyn Water , PEG-80 Water , PEG 80 , Water, Poloxamer, Non-foaming Water, Water USP HOCl 60% HOCl 60% Sorbitan Laurate Sorbitan Laurate Polyethylene, pH
Slide 18: Avenova Beneficial at All Severity Levels of Dry Eye
Avenova Beneficial at All Severity Levels of Dry Eye Treatment Recommendations by Severity Levels 18
Slide 19: Direct Buy & Bill Sales and Prescriptions Sales by Quarter
3,905 3,620 882 3,088 842 Direct Buy & Bill Sales 23% 2,578 Prescriptions Sales 1,003 914 1,580 1,366 3,023 2,778 77% 1,118 70% 1,115 2,085 806 813 1,664 797 465 684 425 30% 465 553 321 40 122 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 19
Slide 20: Multipronged Commercial Strategy
Multipronged Commercial Strategy • Focus on Rx marketing strategy • Ophthalmology channel has greatest growth potential • Avenova pricing model recognizes full value/benefits • Strategy supported by insurance coverage exceeding 90% • Accessible in 90+% of retail pharmacies through distribution agree
Slide 21: Ophthalmic Advisory Board
Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chapters and books. Dr. Richard L
Slide 22: Optometry Advisory Board
Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry-Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally recognized expert in complex co
Slide 23: Advertising: Placements in Top Trade Journals
Advertising Placements in Top Trade Journals Collateral Marketing Materials 23
Slide 24: Interactive Website
Interactive Website Find a Physician Find a Pharmacy 24
Slide 25: Success Stories Written by NovaBay KOLs
Success Stories Written by NovaBay KOLs 25
Slide 26: Success Stories Written by NovaBay KOLs
Success Stories Written by NovaBay KOLs Avenova With Neutrox Is ‘Breakthrough’ in Fight Against New Therapy Introduced for Chronic Dry Eye Contact Lens Intolerance 26
Slide 27: Success Stories Written by NovaBay KOLs
Success Stories Written by NovaBay KOLs Dry Eye: A Growing Problem in an Aging Population New Treatments for Contact Lens Intolerance On The Rise 27
Slide 28: Financial Overview
Financial Overview Million Market Cap (7/14/17) $60 Cash (3/31/17) $7.4 Debt $0 Shares Outstanding (3/31/17) 15.3 (Excludes: Stock Options of 2.2M; Warrants of 0.5M) 2017 Guidance – Total Annual Sales $19 2017 Guidance – Annual Net Cash Burn ($3) 28
Slide 29: In Summary…
In Summary… • Significant commercial opportunity with Avenova • Proprietary formulation with proven antimicrobial properties • Addresses largely untapped market of 41 million Americans • Proven commercial strategy to increase prescriptions and capitalize on insurance reimbursement to drive revenues
NovaBay Pharmaceuticals — Investor Presentation (July 2017) on 6ix